Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $424000.0.

  • Barinthus Biotherapeutics' Non Operating Income fell 6602.56% to $424000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 859.25%. This contributed to the annual value of $6.7 million for FY2024, which is 877.98% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Non Operating Income is $424000.0, which was down 6602.56% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Non Operating Income peaked at $2.8 million during Q4 2024, and registered a low of -$9.3 million during Q1 2021.
  • Moreover, its 5-year median value for Non Operating Income was $1.4 million (2024), whereas its average is $871105.3.
  • In the last 5 years, Barinthus Biotherapeutics' Non Operating Income plummeted by 142936.96% in 2021 and then skyrocketed by 34758.84% in 2023.
  • Barinthus Biotherapeutics' Non Operating Income (Quarter) stood at $1.5 million in 2021, then grew by 24.98% to $1.9 million in 2022, then fell by 1.73% to $1.9 million in 2023, then surged by 49.2% to $2.8 million in 2024, then tumbled by 84.87% to $424000.0 in 2025.
  • Its last three reported values are $424000.0 in Q3 2025, $2.2 million for Q2 2025, and $920000.0 during Q1 2025.